@article {Zimbelmann1429, author = {Stefanie Zimbelmann and Elisabeth Eppard and Stefan Hauser and Stefan Kuerpig and Anna Yordanova and Markus Essler and Hojjat Ahmadzadehfar}, title = {Hematotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617}, volume = {57}, number = {supplement 2}, pages = {1429--1429}, year = {2016}, publisher = {Society of Nuclear Medicine}, abstract = {1429Objectives Radioligand therapy (RLT) with 177Lu-PSMA-617 (Lu-PSMA) (prostate-specific membrane antigen) is a novel targeted therapy for metastatic prostate cancer. There is a need for further investigation regarding hematotoxicity associated with this therapy, especially in patients who undergo repeated therapies. The aim of this study was to investigate the incidence and severity of hematotoxicity in patients who received Lu-PSMA. Methods Ninety-four RLT were performed in 43 Hormone and/or chemorefractory patients (1-4 cycles; median: 2 cycles) with distant metastases and progressive disease (mean age: 72 y/o). Gleason-Score 6-10 (median: 8). 68Ga-PSMA PET/CT was performed in all patients 1-2 weeks prior to RLT. Mean PSA was 734 ng/ml (range: 4.7--5910).Fifteen patients had a history of therapy with Ra-223 (1-6 cyles, median: 5 cycles) and 25 had had a chemotherapy, of whom seven patients had had first- and second-line chemotherapy. All patients received complete blood counts on the day before application (median administered activity 6 GBq). The hematotoxicity was measured according to the CTC criteria version 4. Results The follow-up time was at least two months after the last cycle. Mean Hb, WBC and Plt counts prior to the first cycle were 10,9 g/dl, 6,2 G/l and 274 G/l, respectively. Six patients had a tumor anemia Prior to the first cycle and had received a blood transfusion. Thirty-two patients did not show any hematotoxicity. Anemia grade 1, 2 and 3 occurred in 1, 9 and 4 patients, respectively. Leucopenia grade 1 and 2 occurred in 5 and 4 patients, respectively. Thrombocytopenia grade 1, 2 and 3 occurred in 5, 1 and 3 patients respectively. No patients showed a grade 4 hematotoxicity. Conclusions Although the patients who receive Lu-PSMA therapy are in an advanced stage of their disease, the probability of severe hematotoxicity is under 10\%.}, issn = {0161-5505}, URL = {https://jnm.snmjournals.org/content/57/supplement_2/1429}, eprint = {https://jnm.snmjournals.org/content}, journal = {Journal of Nuclear Medicine} }